Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Interferón beta recombinante o acetato de glatirámero para retrasar la conversión del primer evento desmielinizante en la esclerosis múltiple

Información

DOI:
https://doi.org/10.1002/14651858.CD005278.pub3Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 23 abril 2008see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Esclerosis múltiple y enfermedades raras del sistema nervioso central

Copyright:
  1. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Marinella Clerico

    Correspondencia a: Clinical and Biological Science Department, University of Torino, San Luigi Gonzaga University Hospital, Orbassano, Italy

    [email protected]

  • Fabrizio Faggiano

    Department of Medical Sciences, University of Piemonte Orientale A. Avogadro, Novara, Italy

  • Jaqueline Palace

    University Department of Clinical Neurology, Radcliff Infirmary Hospital, Oxford, UK

  • George PA Rice

    Clinical Neurological Sciences, University of Western Ontario, London, Canada

  • Mar Tintorè Subirana

    Clinical Neuroimmunology Unit, Vall d'Hebròn University Hospital, Barcelona, Spain

  • Luca Durelli

    Clinical and Biological Science Department, University of Torino, San Luigi Gonzaga University Hospital, Orbassano, Italy

Contributions of authors

Dr. Durelli conceived the idea and with all the other reviewers developed the review .

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • Associazione Firni, Italy.

  • Regione Piemonte, Italy.

Declarations of interest

Dr. Clerico hasn't conflict of interest to declare.
Prof. Faggiano hasn't conflict of interest to declare.
Dr. Palace has received financial support for multicenter clinical trials, running a National MS database, attending advisory committees, giving lectures, attending international meetings from TEVA, BIOGEN, SERONO and SCHERING.
Prof Rice has participated in clinical trials sponsored by SCHERING, SERONO, BERLEX, BIOGEN, and TEVA. He has received honoraria from these companies.
Dr. Tintorè was an investigator in the ETOMS study and has received occasionally honoraria as faculty in scientific meetings and her group has received grants from the major interferon beta/glatiramer acetate drug companies.
Prof. Durelli served as steering committee member and as investigator of ETOMS trial; in addition he received consultant fees from SCHERING, SERONO, and BIOGEN.

Acknowledgements

We wish to thank Dr. Graziella Filippini for her useful comments during the preparation of the manuscript.

Version history

Published

Title

Stage

Authors

Version

2008 Apr 23

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Review

Marinella Clerico, Fabrizio Faggiano, Jaqueline Palace, George PA Rice, Mar Tintorè Subirana, Luca Durelli

https://doi.org/10.1002/14651858.CD005278.pub3

2006 Oct 18

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Protocol

Marinella Clerico, Fabrizio Faggiano, Jacqueline A Palace, George PA Rice, M Tintorè, Luca Durelli, Mar Tintorè Subirana

https://doi.org/10.1002/14651858.CD005278.pub2

2005 Apr 20

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Protocol

Marinella Clerico, Fabrizio Faggiano, Jacqueline Palace, George PA Rice, M Tintorè, Luca Durelli, Mar Tintorè Subirana

https://doi.org/10.1002/14651858.CD005278